Browsing: Wellness Tips

CHILDREN in the United Kingdom have some of the worst outcomes for children in Europe, according to a new report from the Royal College of Paediatrics and Child Health (RCPCH)

Medicare spent years refusing to pay for GLP-1 drugs prescribed only for weight loss. A new program called the GLP-1 Bridge changes that, although only partway and only for a limited time

Food companies are beginning to move away from growth strategies centered on volume and toward higher-value products as obesity-treatment drugs gain ground

Under a recently launched Medicare pilot program, millions of older adults may qualify for GLP-1 weight loss drugs

This is a paid press release. Contact the press release distributor directly with any enquiries.

An average weight loss of 17 per cent, achieved by taking one tablet every morning: this is the data that convinced the European Commission to authorise the marketing of semaglutide 25 mg tablets (Novo Nordisk). For the first time in Europe, an oral treatment has been added to the therapeutic arsenal for weight management, alongside…

The Wegovy pill contains semaglutide 25 mg and is taken once daily. The approval is based on the OASIS programme, including the OASIS 4 study in 307 adults with obesity or overweight and at least one weight-related comorbidity. The study demonstrated a mean weight loss of 17 per cent compared with 3 per cent for…

Responding to the Health and Social Care Committee Report: Food and Weight Management: Fixing the food environment, 

New research from Columbia University found that adults who cut their sleep by about 80 minutes for six weeks packed on a pound (0.45 kg) and moved less during the day

Semaglutide has already transformed the treatment of obesity and type 2 diabetes, with benefits extending to cardiovascular and kidney health in appropriately selected patients. Now, an exploratory study has raised another intriguing possibility—that the medication could influence biological ageing